Valuation: Daxor Corporation

Market Cap 61.3M 53.07M 49.48M 45.53M 85.9M 5.83B 86.89M 581M 228M 2.92B 230M 225M 9.67B P/E 2026 *
-50.1x
P/E 2027 * -351x
Enterprise Value 61.3M 53.07M 49.48M 45.53M 85.9M 5.83B 86.89M 581M 228M 2.92B 230M 225M 9.67B EV / Sales 2026 *
5.15x
EV / Sales 2027 * 2.95x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week-0.47%
Current month-0.19%
1 month+0.96%
3 months-3.44%
6 months-14.52%
Current year-28.95%
1 week 10.11
Extreme 10.1101
11
1 month 10.05
Extreme 10.05
11.97
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-0.47%+5.12%+9.36% 61.3M
+4.08%+5.62%+24.15%+112.92% 14.64B
+4.55%+9.47%+59.42%+150.99% 12.23B
-0.20%+4.45%-3.90%+31.14% 9.37B
+4.17%+6.87%+37.61%+132.77% 7.54B
-0.80%-0.31%-16.99%-17.29% 7.45B
-0.23%+0.35%+14.49%+42.70% 6.38B
-0.13%-0.52%+9.26%+23.11% 4.76B
-0.65%-2.64%+8.53%+6.37% 4.05B
-0.65%+4.70% - - 3.83B
Average +1.13%+1.95%+15.30%+54.67% 7.81B
Weighted average by Cap. +1.88%+2.29%+20.63%+76.29%

Financials

2026 *2027 *
Net sales 11.9M 10.3M 9.6M 8.84M 16.67M 1.13B 16.87M 113M 44.25M 566M 44.69M 43.71M 1.88B 20.8M 18.01M 16.79M 15.45M 29.14M 1.98B 29.48M 197M 77.34M 989M 78.11M 76.4M 3.28B
Net income -1.2M -1.04M -969K -891K -1.68M -114M -1.7M -11.38M -4.46M -57.08M -4.51M -4.41M -189M -200K -173K -161K -149K -280K -19.02M -283K -1.9M -744K -9.51M -751K -735K -31.54M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
26-08-05 US$10.48 -0.38% 314
26-08-04 US$10.52 -3.04% 3,119
26-08-03 US$10.85 +3.33% 689
26-07-31 US$10.50 - 870
26-07-30 US$0.000000 -100.00% 115
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.52USD
Average target price
22.50USD
Spread / Average Target
+113.88%

Quarterly revenue - Rate of surprise